Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00324974 · ClinicalTrials.gov registry record · Phase 3
The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 162
- Enrollment target
NCT00324974 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 162 participants.
The verdict
NCT00324974, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 162 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of lansoprazole microgranules oral suspension, once daily (QD), in infants with gastroesophageal reflux symptoms during a 4-week treatment period.
Interventions
- DRUG Placebo
- DRUG Lansoprazole microgranules suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00324974
The ClinicalTrials.gov registry entry for NCT00324974 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00324974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00324974 about?
NCT00324974 is a clinical study titled "The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux". The purpose of this study is to assess the safety and efficacy of lansoprazole microgranules oral suspension, once daily (QD), in infants with gastroesophageal reflux symptoms during a 4-week treatment period.
What is the current status of trial NCT00324974?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 162 participants. The study started on 2006-06. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00324974?
The interventions under investigation include: Placebo (DRUG), Lansoprazole microgranules suspension (DRUG).
Who is sponsoring clinical trial NCT00324974?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.